KOD News and Press, Kodiak Sciences Inc

2026-03-31 16:49:28 ET More on Kodiak Sciences Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines Kodiak Sciences Inc. (KOD) Presents at Angiogenesis, Exudation, and Degeneration 2026 - Slideshow Kodiak Sciences: A Stellar Move ...

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results PR Newswire PALO ALTO, Calif. , March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the ...

2026-03-30 14:10:12 ET More on healthcare stocks IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Routine Vaccines Okay For Now: Investment Implications Of The Court Decision Sector Rotation: Healthcare XLV Should Be The Next Stop Notable hea...

2026-03-27 12:01:34 ET Investment Overview The stock of Palo Alto, California based Kodiak Sciences Inc. ( KOD ) soared in value yesterday, reaching a high of $75 per share (market cap of $2.43bn), as the company announced positive results from its GLOW2 Phase 3 superiority stud...

2026-03-26 09:53:26 ET Denver, Colorado - Lunai Bioworks (NASDAQ:LNAI) is leaning into the growing intersection of artificial intelligence and national security with the launch of its Pathfinder Consortium, a unified platform designed to accelerate chemical countermeasure development to rou...

2026-03-26 07:04:10 ET More on Kodiak Sciences Kodiak Sciences Inc. (KOD) Presents at Angiogenesis, Exudation, and Degeneration 2026 - Slideshow Kodiak Sciences: A Stellar Move Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference - Sli...

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham PR Newswire Building on the success of GLOW1 and with all patients on a 6-month dosing interv...

2026-03-17 20:54:19 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 02/17/2026. The 13F portfolio value increased from $...

2026-03-09 10:06:30 ET Boxer Capital Management, LLC reported a buy of 386,000 Kodiak Sciences (NASDAQ:KOD) shares in its February 17, 2026, SEC filing, an estimated $7.90 million trade based on quarterly average pricing. In a February 17, 2026, SEC filing , Boxer Capital Ma...

2026-02-23 13:40:26 ET On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 2,608,696 shares of Kodiak Sciences (NASDAQ:KOD) , an estimated $53.42 million trade based on quarterly average pricing. According to its SEC filing dated February 17, 2026, Baker Bros. A...